Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 537-540

  Kusumi, Ichiro ^a   Honda, Minoru ^b   Ito, Koichi ^c   Uemura, Keiichi ^d   Kumazawa, Yukie ^c,e   Ishikane, Tomohito ^f   Niide, Yasushi ^g   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Honda Memorial Hospital   (Japan)

^c Sapporo Hanazono Hospital   (Japan)

^d SAPPORO CITY GENERAL HOSPITAL   (Japan)

^e San ai Hospital   (Japan)

^f Ishikane Hospital   (Japan)

^g Yakumo General Hospital   (Japan)

Author keywords

Effectiveness; Oral solution; Risperidone; Schizophrenia; Standard tablet

Indexed keywords

PROLACTIN; RISPERIDONE;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; TABLET; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SOLUTIONS; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952902621     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.12.010     Document Type: Article

References (13)

1. Currier G.W., Simpson G.M. Risperidone liquid concentrate and oral lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001, 62:153-157.
2. Gaebel W., Riesbeck M., von Wilmsdorff M., Burns T., Derks E.M., Kahn R.S., et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 2010, 20:310-316.
3. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
4. Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage 1996, Seiwa Shoten Publishers, Tokyo.
5. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) rating manual 1991, Multi-Health System Inc., Toronto.
6. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychiatry 1999, 19:57-61.
7. Kobayakawa H., Fujita Y., Nakano K., Shibasaki C., Hikasa S., Takebayashi M. A case showing improvement of both psychotic and extrapyramidal symptoms by switching resperidone tablet to its oral solution. Seishin Igaku 2008, 50:375-378. (in Japanese).
8. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
9. Menza M.A., Murray G.B., Holmes V.F., Rafuls W.A. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987, 48:278-280.
10. Risperdal Package Insert. Janssen Pharmaceutical, K.K., Japan (in Japanese), 2002.
11. Toda H., Kusumi I., Sasaki Y., Ito K., Koyama T. Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium. Int Clin Psychopharmacol 2005, 20:331-333.
12. Uemura K., Takahashi Y., Yasuda M. Decreased adverse effects with risperidone oral solution: report of five cases. Seishin Igaku 2006, 48:773-775. (in Japanese).
13. Yoda H., Yamashita H. Comparison of plasma levels between oral solution and fine granule dosage forms of risperisone. Int J Psychiatry Clin Pract 2009, 13:199-205.